# SEC Form 4

[

# FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287							
Estimated average burden								
hours per response	: 0.5							

<ul> <li>Obligations may Instruction 1(b).</li> </ul>			pursuant to Section 16(a) of the Securities Exchange Act of 1934									
			or Section 30(h) of the Investment Company Act of 1940	•								
1. Name and Addre Bonner Mich (Last)		ng Person <sup>*</sup> (Middle)	2. Issuer Name and Ticker or Trading Symbol CUMBERLAND PHARMACEUTICALS INC [ CPIX ] 3. Date of Earliest Transaction (Month/Day/Year)	(Check a	II applicable Director Officer (give below)	10% Owner ive title Other (specify below)						
2525 WEST EN	ID AVENU	E, SUITE 950	03/18/2020		Chief Financial Officer							
(Street) NASHVILLE (City)	TN (State)	37203 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	Line) X	Form filed I	by One Repo	(Check Applic rting Person One Reporting					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code         V         Amount         (A) or (D)         Price         Reported Transaction(s) (Instr. 3 and 4)			(1150.4)				
Common Stock	03/18/2020		F		2,134 <sup>(1)</sup>	D	\$3.53	17,787	D	
Common Stock	03/23/2020		A		2,500 <sup>(2)</sup>	A	\$3.56	20,287	D	

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

								•							
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of E		6. Date Exerc Expiration Da (Month/Day/Y	Amount of Securities		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form:	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. This transaction represents shares purchased by the Company to cover the tax withholding obligations for the vesting of shares.

2. Restricted stock award will vest 100% on March 23, 2024.

Remarks:

## Michael Bonner

\*\* Signature of Reporting Person Date

04/17/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See